Kenvue (HAM:J4D) Valuation Rank


HAM:J4D Kenvue Inc HAM:J4D
66 GF Score
Price €17.16
GF Value €17.64
! 6 Warning Signs
View Full Analysis

What is Kenvue Valuation Rank?

The Valuation Rank measures the current valuation of a business relative to other companies in the same industry and its own historical valuation. The companies are split in equal numbers and then ranked from 1 to 10, with 10 as the most undervalued and 1 as the most overvalued.

  1. Three factors:
    • Absolute valuation (medpsvalue) relative to current stock price, rank among all companies
    • Historical valuation over the past 10 years. Rank pe, ps, pocf, ev2ebit over their own historical values
    • Industry relative valuation
  2. Companies without enough data is not ranked
  3. Companies with negative earnings are ranked lower

These three factors are used to calculate the value score for every eligible company, with values from 1 to 10. The final ranked companies are split in equal numbers and ranked from 1 to 10, with 10 as the most undervalued, and 1 as the most overvalued. The numbers of companies in each rank are the same.

Kenvue Valuation Rank Related Terms

HAM:J4D
66GF Score
Kenvue Inc HAM:J4D
Valuation Rank is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is Kenvue (HAM:J4D) Overvalued in 2026?

Based on GuruFocus' analysis, Kenvue stock appears to be undervalued. The current stock price of €17.16 is trading 2.7% below its estimated GF Value™ of €17.64.

Key valuation signals for HAM:J4D:

  • Valuation Rank:
  • GF Value™: €17.64 vs. price of €17.16 (2.7% below fair value)
  • GF Score™: 66/100 with 6 warning signs

No single metric tells the full story. See the HAM:J4D stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Kenvue Business Description

Address 1 Kenvue Way, Summit, NJ, USA, 07901
Kenvue is the world's largest pure-play consumer health company by sales, generating over $15 billion in annual revenue. Formerly known as Johnson & Johnson's consumer segment, Kenvue spun off and went public in May 2023. It operates in a variety of categories within consumer health, such as cough, cold, and allergy care, pain management, face and body care, and oral care, as well as women's health. Its portfolio has some of the most well-known brands in the space, including Tylenol, Listerine, Johnson's, Aveeno, and Neutrogena. Kenvue announced in November 2025 that it signed a deal to be fully acquired by Kimberly-Clark, with the deal expected to close during the second half of 2026.
66GF Score

Get the complete analysis for HAM:J4D

Valuation Rank is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€17.16
Price
€17.64
GF Value